NeuroQuant®: Contrast agents not required

Factors which degrade the technical quality of MR images or pathologic processes, which significantly affect neuroanatomic structure, may decrease the accuracy of NeuroQuant® output. One of these factors is the use of contrast agents.

Contrast agents are typically used to study vasculature, something that is not needed for volumetric MR imaging. NeuroQuant requires a non-contrasted, 3D T1 sagittal sequence to segment and measure brain structure volumes.

NeuroQuant does not support a contrast enhanced study. The presence of contrast will cause misregistration of cortical and subcortical structures. The segmentation, volumetrics and normative comparisons will be inaccurate when contrast agents are used.

Some examples of NeuroQuant processed with and without contrast agents are shown below.

Cortechs.ai | NeuroQuant<sup>®</sup>: Contrast agents not required

More information about using NeuroQuant can be found here.

Insights

02/09/2025

NeuroQuant® MS:  Advancing Precision in Multiple Sclerosis

Dr. Suzie Bash discusses NeuroQuant MS, noting its ability to segment plaques, analyze volume, and track lesion burden for assessing disease progression

02/09/2025

Epilepsy Care with NeuroQuant Seizure: The Power of Quantifying Hippocampal Asymmetry

Accurate imaging of the hippocampus is crucial for effective diagnosis and treatment planning in TLE, with structural abnormalities linked to seizure onset

02/06/2025

Cortechs.ai and EDAP Announce World’s First OnQ™ Prostate-Assisted Focal One® Robotic HIFU Procedure at UCSF Prostate Cancer Center

This milestone marks the first clinical use of OnQ Prostate’s RSI technology to guide focal therapy, improving lesion localization and targeting for urologists.
Scroll to Top